'Unique Oncology Platform': Gilead (GILD) Earns Two Upgrades After Beat-and-raise Quarter
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Gilead Sciences (GILD) PT Raised to $86 at Jefferies
October 28, 2022 8:59 AM EDTJefferies analyst Michael Yee raised the price target on Gilead Sciences (NASDAQ: GILD) to $86.00 (from $78.00) while maintaining a Buy rating following results.
The analyst commented, "GILD put up a good Q across the board and esp strong Veklury Covid quarter... More
Gilead Sciences (GILD) PT Raised to $87 at JPMorgan
October 28, 2022 7:58 AM EDTJPMorgan analyst Chris Schott raised the price target on Gilead Sciences (NASDAQ: GILD) to $87.00 (from $80.00) while maintaining a Overweight rating.... More
Gilead Sciences (GILD) PT Raised to $75 at Wells Fargo
October 28, 2022 7:27 AM EDTWells Fargo analyst Mohit Bansal raised the price target on Gilead Sciences (NASDAQ: GILD) to $75.00 (from $74.00) while maintaining a Equal Weight rating.... More
Gilead Sciences (GILD) PT Raised to $82 at RBC Capital
October 28, 2022 6:13 AM EDTRBC Capital analyst Brian Abrahams raised the price target on Gilead Sciences (NASDAQ: GILD) to $82.00 (from $79.00) while maintaining a Outperform rating.... More
